Renaissance Capital logo

Zhong Yuan Bio-Technology Holdings Filed, US Offering, Removed, Nasdaq: ZYB

Chinese producer of nervonic acid dietary supplements for cognitive health.

Industry: Consumer Staples

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Consumer Staples

Bao Feng, which conducts business operations in China, is our sole operating subsidiary. Bao Feng is in the business of nervonic acid research, the development of nervonic acid based herbal and chemical drugs and the sale of health supplements containing nervonic acid. Nervonic acid is a long chain unsaturated omega 9 fatty acid that is an important component in myelin biosynthesis in the central and peripheral nervous system. Myelin insulates nerve cell axons to increase the speed at which information (encoded as an electrical signal) travels from one nerve cell body to another or from a nerve cell to another type of cell in the body. It is thought that nervonic acid may enhance brain function and prevent demyelination of nerve cells, and that, therefore, it may be effective in retaining or improving the health of the brain, for example in preventing or ameliorating attention-deficit hyperactive disorder (“ADHD”) in children, Alzheimer's disease and mental degradation in the elderly and cerebrovascular disease, as well as promoting normal brain development in premature infants. The role of nervonic acid is also being studied with respect to psychotic illnesses, such as schizophrenia.
more less
IPO Data
IPO File Date 10/27/2022
Offer Price
Price Range $5.00 - $7.00
Offer Shares (mm) 1.1
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $5.00 - $7.00
Offer Shares (mm) 1.1
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
D. Boral Capital
Revere Securities
more
Company Data
Headquarters Hong Kong, China
Founded 2012
Employees at IPO 35
Website www.zhybiotech.com

Zhong Yuan Bio-Technology Holdings (ZYB) Performance